Mika Sunakawa-Kii

The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma.

R. Morita, K. Inokuchi, H. Tamura, 2020, Experimental hematology.

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma

K. Inokuchi, H. Tamura, M. Ishibashi, 2020, Cancers.

Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells

R. Morita, H. Handa, K. Inokuchi, 2021, Molecular Cancer Therapeutics.

Serum soluble CD86 levels correlate with CD86 variant 3 gene expression and are prognostic indicators in myeloma.

N. Komatsu, K. Inokuchi, S. Ito, 2023, Experimental hematology.